SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla falls as its arm gets one observation for Goa facility

21 Jan 2025 Evaluate

Cipla is currently trading at Rs. 1438.60, down by 7.30 points or 0.50% from its previous closing of Rs. 1445.90 on the BSE.

The scrip opened at Rs. 1447.50 and has touched a high and low of Rs. 1464.65 and Rs. 1435.45 respectively. So far 16396 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1702.00 on 09-Oct-2024 and a 52 week low of Rs. 1312.70 on 31-Jan-2024.

Last one week high and low of the scrip stood at Rs. 1464.65 and Rs. 1429.75 respectively. The current market cap of the company is Rs. 116340.84 crore.

The promoters holding in the company stood at 30.92%, while Institutions and Non-Institutions held 52.88% and 16.19% respectively.

United States Food and Drugs Administration (USFDA) has conducted an inspection at the manufacturing facility of Medispray Laboratories, wholly owned subsidiary of Cipla, located in Kundaim, Goa from January 14 - 20, 2025.

On conclusion of the inspection, Medispray received 1 observation in Form 483. The company will work closely with the USFDA and remains committed to address these observations comprehensively within stipulated time.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.


Cipla Share Price

1232.25 3.35 (0.27%)
21-Apr-2026 10:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1224.60
Cipla 1232.25
Zydus Lifesciences 930.25
Lupin 2327.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×